AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00996190
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
Trial: NCT04826510
Drug: Perospirone hydrochloride tablets
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Perospirone (DB08922)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
Trial: NCT04826510
Drug: Lithium Carbonate Pill
RxNorm normalized name: lithium carbonate Pill
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
Trial: NCT03643666
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: before closure of the laparoscopic entering sites the patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone
Trial: NCT03643666
Drug: magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone plus magnesium sulphate 2 gm into the peritoneum at the end of the operation
Trial: NCT04749602
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 mg of the nivolumab will be used intrapleurally (once).
Trial: NCT01751152
Drug: NNC0114-0006
RxNorm normalized name: NNC0114-0006
DrugBank: NNC0114-0006 (DB18361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
Trial: NCT00655642
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
Trial: NCT00655642
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
Trial: NCT00655642
Drug: Promethazine
RxNorm normalized name: Promethazine
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
Trial: NCT04483700
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Tablets administered orally once daily
Trial: NCT04483700
Drug: Placebo to Match Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Tablets administered orally once daily
Trial: NCT00782509
Drug: Olodaterol (BI 1744)
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of low and high doses on efficacy and safety in COPD patients
Trial: NCT03012477
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT03286582
Drug: Clobetasol 0.05% Topical Ointment
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol 0.05% Topical Ointment BID
Trial: NCT01653665
Drug: Leukine
RxNorm normalized name: Leukine
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
Trial: NCT00153907
Drug: Navelbine
RxNorm normalized name: Navelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
Trial: NCT00314938
Drug: PHA-794428
RxNorm normalized name: PHA-767491
DrugBank: PHA-767491 (DB17043)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02382666
Drug: Rolapitant
RxNorm normalized name: Rolapitant
DrugBank: Rolapitant (DB09291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00417274
Drug: Quinacrine
RxNorm normalized name: Quinacrine
DrugBank: Quinacrine (DB01103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg daily
Trial: NCT00175019
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 80 mg, tablets, orally, once daily.
Trial: NCT00175019
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 120 mg, tablets, orally, once daily.
Trial: NCT00175019
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
Trial: NCT02624843
Drug: Benzyl Alcohol Lotion 5%
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: White topical lotion
Trial: NCT01396681
Drug: gemcitabine and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study consists of three phases; Induction chemotherapy phase:Starting 4\~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
Trial: NCT01747850
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).
Trial: NCT01197261
Drug: Oxycodone naloxone prolonged release tablets
RxNorm normalized name: naloxone / oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 tablets/ day
Trial: NCT03389620
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
Trial: NCT00576381
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
Trial: NCT00095381
Drug: forodesine hydrochloride (BCX-1777)
RxNorm normalized name: terbinafine
DrugBank: Forodesine (DB06185)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03789214
Drug: Low Dose Suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low Dose Suvorexant
Trial: NCT03789214
Drug: High Dose Suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High Dose Suvorexant
Trial: NCT04887844
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
Trial: NCT02967731
Drug: 480 Mometasone Furoate Sinus Drug Depot
RxNorm normalized name: mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of Chronic Sinusitis
Trial: NCT00890877
Drug: OC000459 or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pills, active and/or placebo given twice daily for 17 weeks
Trial: NCT00118053
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00118053
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00928954
Drug: gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: increasing to 1200 mg/day
Trial: NCT00928954
Drug: memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: increasing to 40 mg/day
Trial: NCT03230851
Drug: aspirin 50mg bid therapy
RxNorm normalized name: aspirin 50 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg aspirin for at least 5 days followed by aspirin 50mg bid
Trial: NCT03230851
Drug: indobufen 100mg bid therapy
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg aspirin for at least 5 days followed by indobufen 100mg bid
Trial: NCT00479193
Drug: bacitracin/xeroform
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single layer, change every 3 days
Trial: NCT00479193
Drug: Polymem
RxNorm normalized name: DRESSING,POLYMEM
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single layer of Polymen, change every 3 days
Trial: NCT02142244
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Explicated in the protocol arm
Trial: NCT01911494
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
Trial: NCT01911494
Drug: Methyldopa
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
Trial: NCT02433665
Drug: Iopamidol
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
Trial: NCT00527423
Drug: VEGF Trap Eye
RxNorm normalized name: Trapa bicornis seed extract
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT02422823
Drug: Articaine
RxNorm normalized name: Articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
Trial: NCT02422823
Drug: Articaine
RxNorm normalized name: Articaine
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
Trial: NCT03261193
Drug: ITM + Sham QLB
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham subcutaneous non-anesthetic infiltration with saline
Trial: NCT03261193
Drug: ITM + Bupivacaine QLB
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QL plane block with local anesthesia
Trial: NCT01451853
Drug: SPI-1005 Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen
Trial: NCT01451853
Drug: SPI-1005 Middle Dose
RxNorm normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Trial: NCT01451853
Drug: SPI-1005 High Dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Trial: NCT03573297
Drug: Cariprazine
RxNorm normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cariprazine capsules, oral administration, once daily
Trial: NCT00723554
Drug: Iloprost PD-6
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
Trial: NCT00723554
Drug: Iloprost PD-15
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
Trial: NCT03798314
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01232595
Drug: Vancomycin (POC)
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00242320
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
Trial: NCT01199757
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cohort of patients receiving fluticasone furate
Trial: NCT01457573
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
Trial: NCT01457573
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
Trial: NCT01199757
Drug: mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cohort receiving mometasone furoate
Trial: NCT01199757
Drug: fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cohort of patients on fluticasone propionate
Trial: NCT00183820
Drug: paclitaxel, gemcitabine, and oxaliplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Paclitaxel 170 mg/m2 IV d 1 14 days~2. Gemcitabine 800 mg/m2 IV d 1 14 days~3. Oxaliplatin 100 mg/m2 IV d 1 14 days
Trial: NCT01708161
Drug: AMG 479
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 479 is a monoclonal antibody directed against IGF1-R.
Trial: NCT04289142
Drug: Dexmedetomidine Hydrochloride Group
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
Trial: NCT01642979
Drug: Levamisole+cyclosporin A+Glucocorticoids
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
Trial: NCT01642979
Drug: cyclosporin A+Glucocorticoids
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
Trial: NCT05629949
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
Trial: NCT03541564
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03541564
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03106870
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day.
Trial: NCT01644500
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC
Trial: NCT01644500
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00001305
Drug: Humatrope
RxNorm normalized name: Humatrope
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive a subcutaneous injection.
Trial: NCT00553943
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 D1
Trial: NCT00553943
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg D3
Trial: NCT00796900
Drug: Dantrolene
RxNorm normalized name: Dantrolene
DrugBank: Dantrolene (DB01219)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
Trial: NCT02619799
Drug: intrathecal magnesium sulphate,
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
Trial: NCT02619799
Drug: Intrathecal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
Trial: NCT00059852
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no